Amplify Weight Loss Drug & Treatment ETF (THNR)
| Assets | $2.85M |
| Expense Ratio | 0.59% |
| PE Ratio | 19.05 |
| Shares Out | 110,000 |
| Dividend (ttm) | $0.22 |
| Dividend Yield | 0.85% |
| Ex-Dividend Date | Dec 30, 2024 |
| Payout Frequency | n/a |
| Payout Ratio | 15.98% |
| Volume | 576 |
| Open | 26.24 |
| Previous Close | 26.22 |
| Day's Range | 26.01 - 26.24 |
| 52-Week Low | 18.56 |
| 52-Week High | 26.27 |
| Beta | n/a |
| Holdings | 21 |
| Inception Date | May 21, 2024 |
About THNR
Fund Home PageThe Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Top 10 Holdings
74.76% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 16.62% |
| Novo Nordisk A/S | NVO | 9.82% |
| Regeneron Pharmaceuticals, Inc. | REGN | 8.37% |
| Amgen Inc. | AMGN | 7.30% |
| Chugai Pharmaceutical Co., Ltd. | 4519 | 7.13% |
| Merck & Co., Inc. | MRK | 5.63% |
| Roche Holding AG | ROG | 5.21% |
| AstraZeneca PLC | AZN | 5.21% |
| AbbVie Inc. | ABBV | 4.77% |
| Pfizer Inc. | PFE | 4.69% |
Performance
THNR had a total return of 10.14% in the past year, including dividends. Since the fund's inception, the average annual return has been 2.13%.
News
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
SILJ, HACK, THNR: Trends in Thematic Investing
Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.
Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.